



**TOP-LINE RESULTS**

Phase 3 Dry Eye Disease  
Clinical Trial of Reproxalap

August 8, 2024

Nasdaq: ALDX

© Aldeyra Therapeutics, Inc. 2024

# Disclaimers and Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Aldeyra's possible or assumed future results of operations, expenses and financing needs, business strategies and plans, statements regarding Aldeyra's future expectations, plans and prospects, including, without limitation, statements regarding: FDA agreement with the clinical development and regulatory plan for reproxalap; the outcome and timing of the FDA's review, acceptance, and/or approval of a potential NDA resubmission for reproxalap and the adequacy of the data included in the potential NDA resubmission or the supplemental responses to the FDA; the potential for and timing of regulatory approval; Aldeyra's expectations regarding the exercise of the AbbVie Option; Aldeyra's goals as to the potential profile and benefit of reproxalap in dry eye disease and allergic conjunctivitis, and its other product candidates in the indications for which they are developed; anticipated clinical or regulatory milestones for ADX-2191, ADX-248, ADX-743, ADX-631, and ADX-629, including expectations regarding the results of scheduled FDA meetings and discussions, clinical trial initiations and completions, and the timing and nature of NDA or other submissions to the FDA; Aldeyra's business, research, development and regulatory plans or expectations; political, economic, legal, social, and health risks that may affect Aldeyra's business or the global economy; the structure, timing, and success of Aldeyra's planned or pending clinical trials; and expected milestones, market sizing, pricing and reimbursement, competitive position, regulatory matters, industry environment, and potential growth opportunities, among other things. The results of earlier preclinical or clinical trials may not be predictive of future results. Forward-looking statements include all statements that are not historical facts and, in some cases, can be identified by terms such as "may," "might," "will," "objective," "intend," "should," "could," "can," "would," "expect," "believe," "anticipate," "project," "on track," "scheduled," "target," "design," "estimate," "predict," "contemplates," "likely," "potential," "continue," "ongoing," "aim," "plan," or the negative of these terms, and similar expressions intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Aldeyra's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These statements reflect Aldeyra's current views with respect to future events and are based on assumptions and subject to risks and uncertainties, including the development of, and clinical and regulatory plans or expectations for Aldeyra's investigational new drugs (including reproxalap, ADX-2191, ADX-248, ADX-743, ADX-631, and ADX-629), and systems-based approaches, later developments with the FDA that may be inconsistent with Aldeyra's expectations and beliefs, including the risk that the results from earlier clinical trials, portions of clinical trials, or pooled clinical data may not accurately predict results of subsequent trials or the remainder of a clinical trial for the same or different indications, inconsistent expectations regarding FDA acceptance and review of the company's filings and submitted data sets, and Aldeyra's continuing or post-hoc review and quality control analysis of clinical data. Important factors that could cause actual results to differ materially from those reflected in Aldeyra's forward-looking statements are described in Aldeyra's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as Aldeyra's subsequent filings with the Securities and Exchange Commission. All of Aldeyra's development plans and timelines may be subject to adjustment depending on funding, recruitment rate, regulatory review, which regulatory review timeline may be flexible and subject to change based on the regulator's workload and other potential review issues, preclinical and clinical results, regulatory developments in the United States and other countries, and other factors any of which could result in changes to Aldeyra's development plans and programs or delay the initiation, enrolment, completion, or reporting of clinical trials.

In addition to the risks described above and in Aldeyra's other filings with the SEC, other unknown or unpredictable factors also could affect Aldeyra's results. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. The information in this presentation is provided only as of August 8, 2024, and Aldeyra undertakes no obligation to update any forward-looking statements contained in this presentation on account of new information, future events, or otherwise, except as required by law.



Reproxalap is an investigational new drug and is not available for commercial distribution.

aldeyra



# The Phase 3 Clinical Trial of Reproxalap in a Dry Eye Chamber was Designed to Satisfy the Requirements for NDA Resubmission<sup>†</sup>

## Design

- Randomized, double-masked, vehicle-controlled dry eye chamber challenge

## Dosing

- Visit 1: Medical screening
- Visit 2: Vehicle dry eye chamber (dosing just before and 50 minutes after entry)
- Visit 3: Four doses of randomized treatment (reproxalap or vehicle)
- Visit 4: Randomized dry eye chamber (dosing just before and 50 minutes after entry)

## Size


132 dry eye disease patients: 66 randomized to reproxalap, 66 randomized to vehicle

## Primary Endpoint

Ocular discomfort score from 80 to 100 minutes

## Other Endpoints


Safety



<sup>†</sup>NDA submission requirements depend, in part, on regulatory feedback. Regulatory review and discussion timelines are flexible and subject to change based on the regulator's workload and other potential review issues. Topical ocular reproxalap is an investigational new drug candidate that has been studied in more than 2,500 patients with no observed safety concerns; mild and transient instillation site irritation is the most commonly reported adverse event in clinical trials. NDA = New Drug Application.

aldeyra


# The Phase 3 Dry Eye Chamber Clinical Trial Achieved the Primary Endpoint of Ocular Discomfort




**To our knowledge, the results represent the first positive Phase 3 clinical trial in a dry eye chamber with a symptom as a primary endpoint, and we believe that the results are supportive of the potential rapid clinical effect of reproxalap on reducing ocular discomfort.**

 P value derived from primary endpoint mixed model for repeated measures analysis. Topical ocular reproxalap is an investigational new drug candidate that has been studied in more than 2,500 patients with no observed safety concerns; mild and transient instillation site irritation is the most commonly reported adverse event in clinical trials.

# Aldeyra Believes that Symptom Requirements for Dry Eye Disease NDA Resubmission<sup>†</sup> Have Been Met



**The Phase 3 dry eye chamber clinical trial symptom results are consistent with field trial symptom results previously reviewed by the FDA.**

 <sup>†</sup>NDA submission requirements depend, in part, on regulatory feedback. Regulatory review and discussion timelines are flexible and subject to change based on the regulator’s workload and other potential review issues. Estimates based on primary endpoint mixed model for repeated measures analyses. Topical ocular reproxalap is an investigational new drug candidate that has been studied in more than 2,500 patients with no observed safety concerns; mild and transient instillation site irritation is the most commonly reported adverse event in clinical trials. NDA = New Drug Application; FDA = U.S. Food & Drug Administration.



## Aldeyra Believes that Positive Results from the Phase 3 Clinical Trial Enable NDA Resubmission<sup>†</sup> of Reproxalap for Dry Eye Disease

- The dry eye chamber clinical trial was designed to satisfy the FDA's single resubmission requirement of "at least one additional adequate and well-controlled study to demonstrate a positive effect on the treatment of ocular symptoms of dry eye."
- Through the Special Protocol Assessment process and additional comments, the FDA provided feedback on the clinical trial protocol and statistical plan.
- Aldeyra believes the Phase 3 clinical trial satisfies the FDA's NDA resubmission requirement. NDA resubmission is anticipated in 2024. Based on FDA guidance, the anticipated review period for the potential NDA resubmission is expected to be six months.

<sup>†</sup>NDA submission requirements depend, in part, on regulatory feedback. Regulatory review and discussion timelines are flexible and subject to change based on the regulator's workload and other potential review issues. Topical ocular reproxalap is an investigational new drug candidate that has been studied in more than 2,500 patients with no observed safety concerns; mild and transient instillation site irritation is the most commonly reported adverse event in clinical trials. NDA = New Drug Application; FDA = U.S. Food & Drug Administration.



aldeyra



# Aldeyra has Entered into an Exclusive Option Agreement with AbbVie Inc. for License to Develop and Commercialize Reproxalap

## Key Terms of Reproxalap Option Agreement

### Option for AbbVie to obtain:

- Co-exclusive license to develop, manufacture, and commercialize reproxalap in the U.S.
- Exclusive license to develop, manufacture, and commercialize outside the U.S.

### Financial terms of license if option exercised:

- Upfront payment of \$100 million less option fees
- \$100 million milestone payment upon U.S. FDA approval in dry eye disease
- \$200 million in additional regulatory and commercial milestones
- Profit and loss share (60% for AbbVie/40% for Aldeyra) from commercialization in U.S.
- Tiered royalties on net sales outside of U.S.


abbvie



The option terminates on the earlier of (a) the 10th business day after the date on which Aldeyra received approval from the U.S. FDA of the NDA for reproxalap in dry eye disease and (b) the date that is 18 months after October 31, 2023. Topical ocular reproxalap is an investigational new drug candidate that has been studied in more than 2,500 patients with no observed safety concerns; mild and transient instillation site irritation is the most commonly reported adverse event in clinical trials.

aldeyra

# Reproxalap Represents a Novel Potential Therapeutic Approach in Dry Eye Disease with Rapid Activity in Clinical Trials



**Dry Eye Disease Afflicts 39 Million or More Adults in the U.S.<sup>†</sup>**



<sup>†</sup>Company estimates and Am J Ophthalmol. 2014;157(4):799-806. Topical ocular reproxalap is an investigational new drug candidate that has been studied in more than 2,500 patients with no observed safety concerns; mild and transient instillation site irritation is the most commonly reported adverse event in clinical trials.

